ライフサイエンスコーパス: potentiator

1 their role as 'delivery systems' or 'immune potentiators'.

2 eptor subunit 1 sensitive to both classes of potentiator.

3 rection of modulation, rendering 5beta-DHP a potentiator.

4 properties of this series as a biased GluN2 potentiator.

5 ewly-described role of elexacaftor as a CFTR potentiator.

6 X-770; Kalydeco), a clinically approved CFTR potentiator.

7 ted by ivacaftor, a clinically approved CFTR potentiator.

8 do[4,3-b]indole core as a novel chemotype of potentiators.

9 acid type A receptors (GABAARs) rather than potentiators.

10 therapeutic benefits of CFTR correctors and potentiators.

11 ing-fused thiadiazine dioxides class of AMPA potentiators.

12 eening for mGluR5 agonists, antagonists, and potentiators.

13 closely related to their potencies as mGluR5 potentiators.

14 ity of multiple classes of allosteric mGluR1 potentiators.

15 ation of small-molecule insulin mimetics and potentiators.

16 collection for insulin-receptor agonists and potentiators.

17 s for the development of insulin mimetics or potentiators.

18 ecular mechanism of action for AMPA receptor potentiators.

19 siveness to glucose and several of its known potentiators.

20 he development of antibiotics and antibiotic potentiators.

21 and remarkably, can convert inhibitors into potentiators.

22 eral roles for SMAD2/3 as cell-reprogramming potentiators.

23 of tricyclic sulfonamides as allosteric GlyR potentiators.

24 sphorylation and binding of chloride channel potentiators.

25 ew chemotype to the existing classes of CFTR potentiators.

26 n combination with small-molecule correctors/potentiators.

27 the range of CFTR mutations benefitted by co-potentiators, 14 CF-associated CFTR mutations were studi

28 lifetime, and sensitivity to the allosteric potentiator 3-[3-(3-pyridinyl)-1,2,4-oxadiazol-5-yl]benz

29 s of both the allosteric antagonist MPEP and potentiators 3,3'-difluorobenzaldazine and 3-cyano-N-(1,

30 es the binding affinity of the AMPA receptor potentiator [(3)H]-LY450295 and confers sensitivity to d

31 nenolone sulfate) and the GluN2C/D-selective potentiator [(3-chlorophenyl)(6,7-dimethoxy-1-((4-methox

32 It has been suggested that two allosteric potentiators, 3,3'-difluorobenzaldazine and 3-cyano-N-(1

33 ructural optimization provided highly potent potentiator 32 (AM-3607), which was cocrystallized with

34 of compounds with independent corrector and potentiator activities (termed CoPo).

35 revealed 6 compounds with dual corrector and potentiator activities and 13 compounds with only potent

36 ar EC(50) for DeltaPhe508-CFTR corrector and potentiator activities by short-circuit current assay.

37 compounds with bona fide dual corrector and potentiator activities have not been identified.

38 Compounds with dual corrector and potentiator activities may be useful for single-drug tre

39 Maximal corrector and potentiator activities were comparable with those confer

40 acking conformations to elicit corrector and potentiator activities.

41 onformational requirements for corrector and potentiator activities.

42 R560T, A561E, M1101K and R1162X showed no co-potentiator activity, even with corrector.

43 tiator activities and 13 compounds with only potentiator activity.

44 lectivity versus M1 and M3, with no M2 or M4 potentiator activity.

45 The DeltaF508-CFTR potentiators also activated wild-type and G551D CFTR, al

46 and ivacaftor/tezacaftor brought together a potentiator and a class 1 corrector for F508del homozygo

47 unctionally linking allosteric AMPA receptor potentiator and antagonist sites.

48 ors, axon and dendrite pathfinders, a NeuroD potentiator and other neuronal activities.

49 orms two functions at the synapse: nonlinear potentiator and safety brake.

50 regulate the pharmacology of allosteric AMPA potentiators and antagonists in the cerebellum and hippo

51 In transfected cell systems, certain potentiators and correctors, including VX-809 and VX-770

52 address a different cellular CF defect from potentiators and correctors, our inhibitors provide an a

53 But consideration of these immune potentiators and delivery systems has become important t

54 in, in contrast to the uncharged, allosteric potentiators and inhibitors that also bind within the de

55 AMPA receptor potentiators and non-competitive antagonists represent p

56 d structural features of active and inactive potentiators and successfully predicting the activity of

57 are likely to complicate efforts to identify potentiators and/or correctors of the deltaF508 defect.

58 be recovered by pharmaceutical modulators ("potentiators" and "correctors"), but DeltaF508-CFTR can

59 linical trials combining ivacaftor (a gating potentiator) and lumacaftor (a folding corrector) have p

60 ting CFTR-one boosting ion-channel function (potentiators) and the other increasing plasma membrane d

61 pies, microbiome-based therapies, antibiotic potentiators, and antisense approaches.

62 GABA(A) receptor potentiators are commonly used for the treatment of epil

63 r low potencies, previously described mGluR5 potentiators are not useful for functional studies in na

64 prove CFTR folding (correctors) or function (potentiators) are clinically available.

65 Small-molecule compounds, called potentiators, are known to ameliorate the gating defect.

66 ortant implications for development of AMPAR potentiators as therapeutic agents.

67 The divalent cation Zn(2+) is a potent potentiator at the strychnine-sensitive glycine receptor

68 a potentiator, or converted to inhibitor and potentiator based on concentration.

69 results obtained in previous series of AMPA potentiators belonging to 3,4-dihydro-2H-benzo- and 3,4-

70 Both potentiators bind within the dimer interface of the nond

71 Importantly, the potentiator binding site is adjacent to the "hinge" in t

72 nfers partial sensitivity of [(3)H]-LY450295 potentiator binding to displacement by non-competitive a

73 lyRalpha3cryst to afford the first described potentiator-bound X-ray cocrystal structure within this

74 st acetylcholine (ACh), and agonist ACh with potentiator Ca(2+), to give insight into the conformatio

75 nel open probability, and the dual corrector/potentiator CFFT-001 similarly disrupt interactions betw

76 rted by us for binding of the dual corrector-potentiator CFFT-001 to NBD1 (Hudson et al., 2012), sugg

77 A practical synthesis of a D1 potentiator chiral tetrahydroisoquinoline has been accom

78 ke firing rate was increased by the GluN2C/D potentiator CIQ and decreased by the GluN2C/D antagonist

79 ning, we infused the GluN2C/GluN2D-selective potentiator CIQ bilaterally into the basolateral amygdal

80 s II potentiator') was used with a classical potentiator ('Class I potentiator') such as VX-770 or GL

81 We previously introduced the concept of 'co-potentiators' (combination-potentiators) to rescue CFTR

82 man subject, we speculate that corrector and potentiator combinations may have therapeutic efficacy i

83 Corrector and potentiator combinations were tested in primary cultures

84 the level of activity rather than agonist or potentiator concentration per se.

85 h potentiator-only, corrector-only, and dual potentiator-corrector activities were found.

86 Previous studies showed that the AMPAR potentiators cyclothiazide and 4-[2-(phenylsulfonylamino

87 istent with these findings, an AMPA receptor potentiator delivered into the NAc decreases pain-induce

88 The dihydroisoxazole (DHI) series of AMPAR potentiators described herein originated from the identi

89 fonamides represent the first mGlu2 receptor potentiators discovered.

90 s should be considered in campaigns for CFTR potentiator discovery, and may enable the expansion of V

91 The recent approval of the CFTR potentiator drug ivacaftor (Vx-770) for the treatment of

92 ile effects of acute treatment with approved potentiator drug VX-770 on the rare-mutation panel.

93 monly targeted for therapeutic purposes with potentiator drugs.

94 red gating are candidates for stimulation by potentiator drugs.

95 d membrane localization of CFTR, and/or CFTR potentiators, drugs that increase channel gating, to rea

96 nor previously identified allosteric mGluR1 potentiators [e.g., (S)-2-(4-fluorophenyl)-1-(toluene-4-

97 Co-potentiator efficacy was confirmed in primary human bron

98 Co-potentiator efficacy was found for CFTR missense, deleti

99 However, both a CFTR corrector and potentiator enhanced activity of protein variants genera

100 2,2',3,5'6-pentachlorobiphenyl; a potent RyR potentiator), enhanced synchronized Ca(2+) oscillations

101 ects of a novel low-molecular-weight TMEM16A potentiator (ETX001) were evaluated in human cell and an

102 sted, the most potent activator (E(act)) and potentiator (F(act)) produced large and more sustained C

103 nt at 0 Ca(2+), whereas tetrazolylbenzamide "potentiators" (F(act)) were not active at 0 Ca(2+) but r

104 c niche, suggesting a potential of GABAergic potentiators for pro-neurogenic or cell therapies of AD.

105 antagonist GYKI-53655 displaces binding of a potentiator from brain receptors but not from recombinan

106 t with potentiators in the cocrystal disrupt potentiator function.

107 -5-methyl-4-isoxazolepropionic acid receptor potentiators has been identified using rational and stru

108 h the recent introduction of CFTR correctors/potentiators has revolutionized the clinical management

109 VX-770, a CFTR potentiator, has been shown to increase the activity of

110 acid (R-mTFD-MPAB), an anesthetic and GABAAR potentiator, has been shown to inhibit Torpedo alpha2bet

111 nt and stereoselective anesthetic and GABAAR potentiator, has identified a second class of intersubun

112 ("correctors") or chloride channel gating ("potentiators") have been discovered and are in clinical

113 cribe a potent small molecule sodium channel potentiator ICA00600232 that exhibits >1000-fold selecti

114 The Class II potentiators identified here may have clinical benefit f

115 he amount of CFTR on the cell surface, while potentiators improve the gating function of the CFTR cha

116 ology of VX-770, an orally bioavailable CFTR potentiator in clinical development for the treatment of

117 with the combination of a CFTR corrector and potentiator in people with cystic fibrosis homozygous fo

118 potent pyridothiadiazine-type AMPA receptor potentiator in vitro, whereas the 7-chloro-substituted c

119 nhibition which was prevented by a GluN2C/2D potentiator in wildtype and GluN2C heterozygous mice but

120 better understand treatment efficacy of CFTR potentiators in COPD.

121 er understand the treatment efficacy of CFTR potentiators in COPD.

122 ide conductance was seen with correctors and potentiators in homozygous DeltaF508 cells, increased ch

123 g the binding affinities of subsequent AMPAR potentiators in rat brain homogenate, and PF-04701475 (8

124 int mutations of residues that interact with potentiators in the cocrystal disrupt potentiator functi

125 st example of the efficacy of mGlu2 receptor potentiators in these models.

126 combination with ivacaftor (VX-770), a CFTR potentiator, in patients 12 years of age or older who ha

127 trial to evaluate ivacaftor (VX-770), a CFTR potentiator, in subjects 12 years of age or older with c

128 tural classes of mGluR5-selective allosteric potentiators, including CDPPB, share a common binding si

129 s transmembrane conductance regulator (CFTR) potentiator, is approved for the treatment of patients w

130 ow residual function and respond to the CFTR potentiator ivacaftor in vitro, whereas ivacaftor alone

131 The CFTR potentiator ivacaftor is suggested to improve glucose ho

132 tment of G551D patients with the ion channel potentiator ivacaftor resulted in normalized neutrophil

133 cules, the CFTR corrector lumacaftor and the potentiator ivacaftor, are now used clinically to treat

134 CFTR modulators, including the potentiator ivacaftor, augment channel gating to restore

135 nation with the corrector lumacaftor and the potentiator ivacaftor, it showed an additive effect, as

136 fibrosis transmembrane conductance regulator potentiator (ivacaftor), and a selective estrogen recept

137 ivity of the mutants was rescued by the CFTR potentiator, ivacaftor (VX-770).

138 fibrosis transmembrane conductance regulator potentiator, ivacaftor (VX-770/Kalydeco, Vertex Pharmace

139 However, the only potentiator, ivacaftor, has suboptimal pharmacokinetics

140 nation of the corrector, lumacaftor, and the potentiator, ivacaftor, partially rescues the defective

141 Application of potentiators known to increase P(o) of DeltaF508 CFTR ch

142 'High-impact' AMPAR potentiators like PF-04958242 may have a role in the tre

143 a muscarinic acetylcholine receptor (mAChR) potentiator, LY2119620 (3-amino-5-chloro-N-cyclopropyl-4

144 also suggest that structurally diverse M(1) potentiators may act by distinct mechanisms and differen

145 Hence, the efficacy of potentiators may be obscured by a ceiling effect when dr

146 rotein similar to the macrophage infectivity potentiator (Mip) proteins of Legionella pneumophila and

147 Macrophage infectivity potentiator (MIP) proteins, found in pro- and eukaryotic

148 imerization domain of macrophage infectivity potentiator (Mip) proteins, which are proteins with pept

149 Macrophage infectivity potentiators (Mips) are a group of virulence factors enc

150 The single amino acid "P" (potentiator) mutation in the holoenzyme component GAL11

151 Recently, it was reported that the approved potentiator N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-

152 However, another mGluR5 potentiator, N-{4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-is

153 The twitch potentiator nitrate was shown to increase myoplasmic [Ca

154 e NLRP3 inflammasome in myeloid cells, a key potentiator of age-related inflammation.

155 Cyclothiazide (CTZ), a potentiator of AMPAR, revealed slowly rising AMPA EPSCs

156 has suggested that its product may act as a potentiator of another sex determination gene, tra-2.

157 Expression of GGT1 has been implicated as a potentiator of asthma, cardiovascular disease, and cance

158 oprotein, a powerful inflammatory signal and potentiator of atherosclerosis.

159 s contain the Th1-type cytokine IFN-gamma, a potentiator of atherosclerosis.

160 nd 2 (MRS 2219), was found to be a selective potentiator of ATP-evoked responses at rat P2X1 receptor

161 he role of amyloids as a carrier for DNA and potentiator of autoimmune responses, and we propose a no

162 w, we discuss the role of EBV infection as a potentiator of autoimmune rheumatic diseases.

163 Development of a rationally designed potentiator of cancer chemotherapy, via inhibition of Bc

164 n contrast to exhaustion regulator TOX, as a potentiator of central memory differentiation of CAR T c

165 l properties of BIA as a BTB modulator and a potentiator of chemotherapy, supporting its further deve

166 at Siva-1 or its SAH region can be used as a potentiator of cisplatin-based chemotherapy.

167 ic ether found in plant essential oils, as a potentiator of CPT cytotoxicity in Tdp1 deficient but no

168 lopment candidate with in vivo efficacy as a potentiator of deoxyribonucleic acid (DNA) damaging chem

169 specifically that osmotic swelling acts as a potentiator of downstream signaling, not only for the be

170 However, a suitable light-activated potentiator of GABA(A)Rs has been elusive so far for use

171 g that 5-Aza-CdR should be investigated as a potentiator of IFN responsiveness in certain IFN-resista

172 ker for obesity-induced ATM infiltration and potentiator of interleukin-4 responses and point toward

173 Our study suggests that arsenic might be a potentiator of manganese toxicity.

174 , whereas a previously identified allosteric potentiator of mGluR1 has the opposite effect.

175 arboxamide (PHCCC) is a selective allosteric potentiator of mGluR4.

176 in vivo behavioral effects of an allosteric potentiator of mGluRs and suggest that potentiation of m

177 on of a high throughput screening hit 6 as a potentiator of mutant human F508del and wild-type CFTR c

178 Our results establish that CMPI is a potent potentiator of nAChRs containing analpha4:alpha4 subunit

179 both an inhibitor of AChE and an allosteric potentiator of nAChRs, had similar effects.

180 A novel role for L1 as a potentiator of neuronal cell migration to extracellular

181 ticle, we identify a novel subunit-selective potentiator of NMDA receptors containing the NR2C or NR2

182 ither an inhibitory neurotransmitter or as a potentiator of NMDA-dependent excitatory neurotransmissi

183 that, in combination with Pax9, it acts as a potentiator of Pax9-induced Bmp4 transactivation.

184 tenin signaling has emerged as a significant potentiator of pluripotency: increases in the levels of

185 that Rap1 can act as either a repressor or a potentiator of Ras effector signals, depending on CD45 i

186 , raising the possibility that the nonsterol potentiator of reductase regulation is a geranylgeranyla

187 lacks allosteric agonist activity but acts a potentiator of responses to acetylcholine.

188 an unexpected role of zinc as an allosteric potentiator of small-molecule-induced activation of GPR3

189 or the prevention of cerebral ischemia, as a potentiator of statin anticancer activity.

190 The most likely potentiator of stroke risk in patients with cryptogenic

191 ll type 2 (Th2) cytokine best described as a potentiator of Th2 memory responses.

192 ated Gene 4 (PAGE4) is an IDP that acts as a potentiator of the Activator Protein-1 (AP-1) transcript

193 nctions and identified it to be an important potentiator of the antiproliferative effects of 9-cis-RA

194 Ivacaftor is a potentiator of the CFTR chloride channel and is in world

195 Ivacaftor is a potentiator of the cystic fibrosis transmembrane conduct

196 c acid (BQCA), a highly selective allosteric potentiator of the M(1) mAChR.

197 cuit, suggesting that MEF2C might serve as a potentiator of the transcriptional pathways affected in

198 exhibit enhanced levels of miR-92a (a known potentiator of the Wnt/beta-catenin pathway), and that t

199 -carboxylate), acts as a positive allosteric potentiator of Torpedo nACh receptor (nAChR) and binds t

200 gest that Finb/RREB-1 should be considered a potentiator of transcription, representing a distinct ca

201 genesis, and interleukin-1beta (IL-1beta), a potentiator of VEGF, were detected within 12 and 6 h, re

202 ds are among the most potent and efficacious potentiators of activation of GABA(A) receptors.

203 mes have been widely investigated for use as potentiators of anticancer therapies and as inhibitors o

204 pathogenesis of disease both as triggers and potentiators of beta-cell destruction.

205 on evaluating activity as monotherapy and as potentiators of chemotherapy.

206 re currently under clinical investigation as potentiators of cytotoxic chemotherapy and demonstrate p

207 dentified six novel classes of high affinity potentiators of defective Delta F508-CFTR Cl- channel ga

208 e Delta F508-CFTR processing, small molecule potentiators of defective Delta F508-CFTR gating may be

209 Other potentiators of GABA(A) receptors, including benzodiazep

210 -20-one (tetrahydrodeoxycorticosterone), all potentiators of GABA(A)Rs, inhibited the GABA-elicited c

211 Neuroactive steroids are efficacious potentiators of GABA-A receptors.

212 dent of IL-12 and IL-18, the well-documented potentiators of IFN-gamma expression, and is not produce

213 th a broader therapeutic window, were better potentiators of INH-mediated inhibition of an INH-resist

214 DNA-PK IC = 8 nM) with promising activity as potentiators of ionizing radiation-induced cytotoxicity

215 The role of bile acids as hormones and potentiators of liver cancer is also emerging.

216 Additionally, potentiators of mGlu3 may be useful in alleviating prefr

217 These data suggest that allosteric potentiators of mGluR1 act at a site that is distinct fr

218 nt class of small molecule subunit-selective potentiators of NMDA receptors.

219 Furthermore, examples of known potentiators of PTI, in one case under direct mitogen-ac

220 nthetic small molecules identified active co-potentiators of pyrazoloquinoline, piperidine-pyridoindo

221 e less apparent, carvacrol and thymol act as potentiators of responses evoked by submaximal concentra

222 entially inert to highly efficacious (strong potentiators of single-channel and macroscopic peak resp

223 covery of a new class of positive allosteric potentiators of the metabotropic glutamate receptor 2 (m

224 The strongest potentiators of the trigeminal response were carbonyl co

225 e designed experiments to develop allosteric potentiators of this key prostaglandin receptor.

226 ls that support specific bacterial agents as potentiators of tumorigenesis-including Fusobacterium nu

227 bset of modifier genes serving as buffers or potentiators of variability.

228 Positive allosteric modulators ("potentiators") of alpha-amino-3-hydroxy-5-methyl-4-isoxa

229 that act as positive allosteric modulators (potentiators) of metabotropic glutamate receptor (mGluR)

230 ompared with the use of agonists, allosteric potentiators offer potential advantages such as temporal

231 Stargazin also enhances the effect of AMPAR potentiators on channel deactivation.

232 opy structures of human CFTR in complex with potentiators: one with the U.S.

233 opy structures of human CFTR in complex with potentiators: one with the U.S. Food and Drug Administra

234 Compounds with potentiator-only, corrector-only, and dual potentiator-c

235 Binding of spermine, an allosteric potentiator, opens the amino-terminal domain cleft of bo

236 by 8-fold, and did not show any significant potentiator or antagonist activity at other mGluR subtyp

237 ne remained an inhibitor, transformed into a potentiator, or converted to inhibitor and potentiator b

238 of the GluN2C-selective positive allosteric potentiator (PAM), PYD-106, the agonist-bound GluN1-2A-2

239 ing aged apoE4-KI mice with a GABAA receptor potentiator pentobarbital (PB) before and during behavio

240 g aged apoE4-KI mice with the GABAA receptor potentiator pentobarbital (PB) for 4 weeks before and du

241 eritoneal injections of the GABA(A) receptor potentiator pentobarbital at 20 mg/kg for 4 weeks rescue

242 roinjections of the allosteric AMPA receptor potentiator PEPA during the first 5 days of extinction t

243 The current study assessed whether the AMPAR potentiator PF-04958242 would attenuate ketamine-induced

244 k demonstrates that stargazin controls AMPAR potentiator pharmacology, which has important implicatio

245 ne hydrogen maleate] or the GABA(A) receptor potentiator phenobarbital, which mimics components of th

246 ,2',3,5'6-pentachlorobiphenyl), a potent RyR potentiator, phenocopies the dendrite-promoting effects

247 eptor in the presence of the alpha7-specific potentiator PNU-120596 (PNU).

248 structure determined in the presence of the potentiator PNU-120596 was consistent with an activated

249 ", normalizing DeltaF508-CFTR targeting) and potentiator ("Po", normalizing DeltaF508-CFTR channel ga

250 Furthermore, the GluN2A/B-selective potentiator (pregnenolone sulfate) and the GluN2C/D-sele

251 al. (2017) show that Wnts and Wnt signaling potentiator R-spondins have non-interchangeable roles.

252 s transmembrane conductance regulator (CFTR) potentiator recently approved for patients with CF age 6

253 In rats and nonhuman primates (NHP), AMPAR potentiators reduce spatial working memory deficits caus

254 A recombinant macrophage infectivity potentiator (rMIP) protein of Neisseria meningitidis ind

255 dict that glycans at GluN1-N440 might play a potentiator role in NMDARs.

256 Several novel potentiator scaffolds were identified with efficacy comp

257 be the discovery and optimization of a novel potentiator series.

258 receptor-bilayer interface, in the consensus potentiator site.

259 AMPAR potentiators slow channel deactivation and desensitizati

260 We suggest that the potentiators slow deactivation by stabilizing the clamsh

261 o afford adsorption of small molecule immune potentiator (SMIP) onto alum, thereby enhancing co-deliv

262 ed the utility of a small molecule corrector/potentiator strategy, as used for DeltaF508-CFTR, to pro

263 used with a classical potentiator ('Class I potentiator') such as VX-770 or GLPG1837.

264 Possible approaches for developing CFTR potentiators targeting site 1 will be discussed.

265 tance by up to 8-fold was observed when a co-potentiator (termed 'Class II potentiator') was used wit

266 onic acid), a substrate-selective allosteric potentiator that augments 2-AG oxygenation by up to 3.5-

267 improved by replacement of Ivacaftor with a potentiator that does not interfere with corrector actio

268 R to the cell surface, and ivacaftor, a CFTR potentiator that enhances chloride transport of CFTR on

269 ical corrector, which helps CFTR fold, and a potentiator that increases CFTR channel activity.

270 zed CFTR protein, ivacaftor serves as a CFTR potentiator that increases the open probability of CFTR

271 od of overcoming such resistance is to use a potentiator that is capable of neutralizing the antiapop

272 ies represents the first class of allosteric potentiators that are selective for diheteromeric GluN2C

273 ivity analysis identified several classes of potentiators that do not impair corrector action, includ

274 t the identification and characterization of potentiators that do not interfere with F508-CFTR stabil

275 A panel of CFTR correctors and potentiators that increased DeltaF508-CFTR maturation or

276 benzo-1,4-dioxan-10-one), two AMPA receptor potentiators that preferentially slow AMPA receptor deac

277 correctors that improve folding of CFTR and potentiators that recover the function of CFTR.

278 CF patients under corrector-potentiator therapy, which enhances CFTR transport to th

279 rting points for developing novel antibiotic potentiators, this method could be expanded to other col

280 r" to improve its cellular processing and a "potentiator" to improve its chloride channel function.

281 he concept of 'co-potentiators' (combination-potentiators) to rescue CFTR function in some minimal fu

282 e secretion in our assay than ivacaftor, the potentiator treatment currently available to these patie

283 Notably, CFTR potentiators used to treat cystic fibrosis effectively r

284 ucted a screen of 20,000 compounds for KCNQ2 potentiators using rubidium flux combined with atomic ab

285 mutation K1250A or pretreating with the CFTR potentiator VX-770 (Ivacaftor) imparted resistance to in

286 channel openings, background mutations or a potentiator was used to increase open duration.

287 ds were developed and their activity as AMPA potentiators was characterized.

288 rved when a co-potentiator (termed 'Class II potentiator') was used with a classical potentiator ('Cl

289 Ivacaftor, which is a potentiator, was approved for gating mutations.

290 Quinolinone-3-carboxamide 1, a novel CFTR potentiator, was discovered using high-throughput screen

291 reduced potentiating steroids; 5beta-reduced potentiators were only weakly affected.

292 These potentiators were shown to have no effect in the absence

293 bunit-specific NMDA receptor antagonists and potentiators were used to identify which GluN2 subunits

294 been shown to be a safe and effective immune potentiator when administered therapeutically.

295 report that cathelicidin is a powerful Th17 potentiator which enhances aryl hydrocarbon receptor (AH

296 analogue library synthesis approach provided potentiators with excellent potency and selectivity for

297 isubstituted 4H-chromen-4-ones as potent BMP potentiators with osteogenic efficacy.

298 To identify novel correctors and potentiators with potentially greater efficacy on CFTR12

299 the need for appropriate delivery of immune potentiators with several 'delivery system' adjuvants su

300 tic efficacy, and they can act as antibiotic potentiators, with a mechanism of action orthogonal to s